Doustdar
Biotech

Novo aims for deals to ‘close some gaps’ as misfires hit profits

CEO Mike Doustdar told Fierce that Novo is looking for deals to “close some gaps” in its pipeline after reporting billions in impairment charges.
James Waldron Nov 4, 2026 4:01am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
Boehringer biopharmaceutical manufacturing facility in Shanghai

Boehringer bags $7.4B Sino deal for 6 preclinical TCEs, ADCs

Nov 4, 2026 9:08am
a lot of scissors

Ultragenyx shrinks workforce and axes assets to halve R&D spend

Nov 4, 2026 5:19am
Servier

Servier’s $1.6B muscular dystrophy bet fails pivotal test

Nov 4, 2026 3:06am
Sanofi headquarters Sanofi

Sanofi scraps Nurix program 2 months after entering clinic

Nov 4, 2026 5:02am
More News

Charles River teams up with Ipsen for toxicology studies

Nov 4, 2026 2:25pm

Fierce Biotech Layoff Tracker 2026: Ultragenyx & more

Nov 4, 2026 11:00am
Fierce Pharma

Ex-Madrigal clinical head files Rezdiffra whistleblower suit

Nov 4, 2026 10:49am

Minghui grants ASKA Japan rights to TED candidate in $440M deal

Nov 4, 2026 9:18am